Integrum (INTEG B.ST) Stock Price

Integrum AB generates revenue through the sale of medical devices, primarily the OPRA Implant System, which enables osseointegration for direct skeletal attachment of artificial limbs. The company also offers neural prosthetics technology, allowing bionic prostheses to connect directly to bone, nerves, and muscles, alongside a treatment method for phantom limb pain using machine learning, augmented reality, and virtual reality. Prosthetic components required to link the OPRA Implant System to external prostheses are sold as part of the product suite. Customers include individuals with amputations seeking advanced prosthetic solutions, with the company targeting medical professionals and healthcare providers who recommend and implement these systems. The OPRA Implant System, neural prosthetics, and phantom limb pain treatment are key revenue drivers, with the company focusing on high-end medical devices for specialized applications. Prosthetic components serve as complementary products, supporting the primary systems. The business model relies on direct sales to healthcare institutions and clinics specializing in prosthetics and rehabilitation, where the technology is integrated into patient care pathways. Integrum AB's product portfolio is centered around innovative medical solutions for amputees, with the OPRA Implant System as the flagship offering. The neural prosthetics and phantom limb pain treatment methods differentiate the company in the medical device market, addressing both functional and therapeutic needs. Sales of prosthetic components further enhance revenue streams by supporting the full integration of the implant system with external prosthetic devices.